What are your top takeaways from ASCO GU 2025?

In terms of practice-informing presentations in prostate cancer here are my top 3:

1. GROUQ-PCS 9 trial (Canada, abstract 22). This trial led by Niazi et al tested whether metastasis-directed radiotherapy based on conventional imaging to up to 5 sites provided benefits in delaying rPFS or PSA progressi...

1. ABSTRACT LBA18: Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.

Well done trial, clinically meaningful OS benefit

Caveats

• Would b...

My favorites were

1. Abstract 308 (middle or high veracyte score predicts benefit of dose escalation).
2. Abstract 309 (comparison of 2 trials reveals higher distant metastatic failure rate with a surgical-based approach for high-risk prostate cancer than seen with a radiation-based approach)
3. Abstract 20...

1. TALAPRO-2 overall survival data
2. ENZA-P overall survival data
3. Enzalutamide +/- mevrometostat randomized phase 2 trial